OPEX® Introduces the Next Generation in Goods-to-Person Warehouse Automation Technology - Infinity™ ASRS
OPEX® Corporation, a global leader in warehouse automation technology, has added an innovative, industry-leading goods-to-person (G2P) solution to its Warehouse Automation portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005036/en/
The Infinity Goods-to-Person (G2P) solution (Photo: Business Wire)
The Infinity™ solution combines unparalleled storage density, configurability, and flexibility to meet the most pressing warehouse automation challenges for companies handling micro-fulfillment, omni-channel distribution, store replenishment, and ecommerce.
“Our focus is on engineering exciting new solutions that address unmet and evolving customer needs,” said Alex Stevens, President, OPEX Warehouse Automation. “The Infinity solution represents the next generation of goods-to-person technology to perfectly complement our existing Warehouse Automation product line.”
Automated G2P technology delivers the right item or SKU at the right time to the right operator or workstation, increasing productivity, throughput, and labor utilization by eliminating wasted time.
Powered by OPEX’s proprietary Cortex™ software platform, the Infinity G2P solution is engineered for maximum flexibility and scalability in both throughput and storage. Key benefits include reducing labor while increasing efficiency, storage density, and configurability.
Wireless Infinity iBOT® robotic vehicles access all inventory and port stations, moving freely underneath and throughout the system with no wasted mechanical motion, saving time and costs. Infinity iBOT robots are easily scalable by adding more iBOTs, presentation ports, and grids.
Unlike other competitive systems, the Infinity solution offers up to 35 percent more storage capacity with bot paths that are up to 65 percent more efficient.
The Infinity goods-to-person system utilizes a unique interlocking system to store totes triple-deep, eliminating wasted space and maximizing storage density. A configurable rack design optimizes warehouse space despite obstructions that may exist, such as columns or other equipment. The Infinity system’s flexibility also accommodates varied workflows and layouts.
The innovative Infinity solution was unveiled today at MODEX 2022, the industry’s premier material handling expo that showcases the latest in manufacturing and supply chain technology.
“Ecommerce is growing exponentially,” said Stevens. “Companies today need dependable yet advanced technology, the resiliency to meet shifting and seasonal demands, fast and accurate fulfillment, the ability to maximize space, and a partner they can trust. OPEX and the Infinity solution deliver all of this and more.”
Founded in 1973, OPEX brings generations of industry expertise and a proven track record developing first-class automation capabilities. The company is vertically integrated—innovating, engineering, manufacturing, selling, and servicing all of its automated solutions. This translates to the highest degree of quality equipment, reliable operations, product longevity, and an exceptional client experience.
The Infinity solution joins the existing Warehouse Automation portfolio at OPEX, which includes Sure Sort®—the industry-leading, high-speed, small-item robotic sorting system; and Perfect Pick®, a robotic goods-to-person picking solution that dramatically improves speed, efficiency, and reliability. All three solutions are custom configured for each client and designed to completely transform supply chain infrastructure.
To learn more, please visit warehouseautomation.com.
About OPEX
OPEX Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ, USA—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has more than 1,500 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005036/en/
Contact information
Colleen Ciak
cciak@opex.com
+1 856.727.1100, ext. 5350
+1 856.912.4952 Cell
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
